| Verf.angabe: | Henrik Petrowsky, MD, Michael Linecker, MD, PhD, Dimitri A. Raptis, MD, PhD, Christoph Kuemmerli, MD, Ralph Fritsch, MD, Onur E. Kirimker, MD, Deniz Balci, MD, Francesca Ratti, MD, Luca Aldrighetti, MD, Sergey Voskanyan, MD, Federico Tomassini, MD, Roberto I. Troisi, MD, Jan Bednarsch, MD, Georg Lurje, MD, Mohammad-Hossein Fard-Aghaie, MD, Tim Reese, MD, Karl J. Oldhafer, MD, Omid Ghamarnejad, MD, Arianeb Mehrabi, MD, Mauro E. Tun Abraham, MD, Stephanie Truant, MD, Francois-Rene ́Pruvot, MD, Emir Hoti, MD, Patryk Kambakamba, MD, Ivan Capobianco, MD, Silvio Nadalin, MD, Eduardo S.M. Fernandes, MD, MSc, Philipp Kron, MD, Peter Lodge, MD, Pim B. Olthof, MD, PhD, Thomas van Gulik, MD, PhD, Carlos Castro-Benitez, MD, PhD, Rene Adam, MD, Marcel Autran Machado, MD, Martin Teutsch, MD, Jun Li, MD, Marcus N. Scherer, MD, Hans J. Schlitt, MD, Victoria Ardiles, MD, Eduardo de Santibanes, MD, PhD, Roberto Brusadin, MD, Victor Lopez-Lopez, MD, Ricardo Robles-Campos, MD, Massimo Malago, MD, Roberto Hernandez-Alejandro, MD, and Pierre-Alain Clavien, MD, PhD |
|---|
| Abstract: | Objectives: - To analyze long-term oncological outcome along with prognostic risk factors in a large cohort of patients with colorectal liver metastases (CRLM) undergoing ALPPS. - Background: - ALPPS is a two-stage hepatectomy variant that increases resection rates and R0 resection rates in patients with primarily unresectable CRLM as evidenced in a recent randomized controlled trial. Long-term oncologic results, however, are lacking. - Methods: - Cases in- and outside the International ALPPS Registry were collected and completed by direct contacts to ALPPS centers to secure a comprehensive cohort. Overall, cancer-specific (CSS), and recurrence-free (RFS) survivals were analyzed along with independent risk factors using Cox-regression analysis. - Results: - The cohort included 510 patients from 22 ALPPS centers over a 10-year period. Ninety-day mortality was 4.9% and median overall survival, CSS, and RFS were 39, 42, and 15 months, respectively. The median follow-up time was 38 months (95% confidence interval 32-43 months). Multivariate analysis identified tumor-characteristics (primary T4, right colon), biological features (K/N-RAS status), and response to chemotherapy (Response Evaluation Criteria in Solid Tumors) as independent predictors of CSS. Traditional factors such as size of metastases, uni versus bilobar involvement, and liver-first approach were not predictive. When hepatic recurrences after ALPPS was amenable to surgical/ablative treatment, median CSS was significantly superior compared to chemotherapy alone (56 vs 30 months, P < 0.001). - Conclusions: - This large cohort provides the first evidence that patients with primarily unresectable CRLM treated by ALPPS have not only low perioperative mortality, but achieve appealing long-term oncologic outcome especially those with favorable tumor biology and good response to chemotherapy. |
|---|
Online-Ressource
